Immune Response to SARS-CoV-2 in an Asymptomatic Pediatric Allergic Cohort
Disease-specific COVID-19 pediatric comorbidity has not been studied effectively to date. Atopy and food anaphylaxis disease states require improved characterization of SARS-CoV-2 infection risk. To provide the first such characterization, we assessed serum samples of a highly atopic, food anaphylac...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-06-01
|
Series: | Antibodies |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4468/10/2/22 |
_version_ | 1797531691190845440 |
---|---|
author | Nathan L. Marsteller Diana J. Fregoso Tricia L. Morphew Inderpal S. Randhawa |
author_facet | Nathan L. Marsteller Diana J. Fregoso Tricia L. Morphew Inderpal S. Randhawa |
author_sort | Nathan L. Marsteller |
collection | DOAJ |
description | Disease-specific COVID-19 pediatric comorbidity has not been studied effectively to date. Atopy and food anaphylaxis disease states require improved characterization of SARS-CoV-2 infection risk. To provide the first such characterization, we assessed serum samples of a highly atopic, food anaphylactic, asymptomatic pediatric cohort from across the US during the height of the pandemic. From our biobank, 172 pediatric patient serum samples were characterized specific to atopic, food anaphylactic, and immunologic markers in the US at the beginning of the pandemic, from 1 February to 20 April 2020. Clinical and demographic data were further analyzed in addition to sample analysis for SARS-CoV-2 IgM and IgG ELISA. SARS-CoV-2 antibody results were positive in six patients (4%). Nearly half of the pediatric patients had a history of asthma (49%). Total IgE, total IgG, and IgG1-3 were similar in those positive and negative to SARS-CoV-2. Median total IgG4 in the SARS-CoV-2 positive group was nearly three times (<i>p</i>-value = 0.02) that of the negative group. Atopy controller medications did not confer additional benefit. Our data suggest that food anaphylaxis and highly atopic children are not at increased risk for SARS-CoV-2 seropositivity. This specific population appears either at equal or potentially less risk than the general population. Total and specific IgG4 may be a novel predictor of SARS-CoV-2 infection risk specific to the allergic pediatric population. |
first_indexed | 2024-03-10T10:47:21Z |
format | Article |
id | doaj.art-f4dcb55d4cb84dc08af5618a261e486c |
institution | Directory Open Access Journal |
issn | 2073-4468 |
language | English |
last_indexed | 2024-03-10T10:47:21Z |
publishDate | 2021-06-01 |
publisher | MDPI AG |
record_format | Article |
series | Antibodies |
spelling | doaj.art-f4dcb55d4cb84dc08af5618a261e486c2023-11-21T22:31:17ZengMDPI AGAntibodies2073-44682021-06-011022210.3390/antib10020022Immune Response to SARS-CoV-2 in an Asymptomatic Pediatric Allergic CohortNathan L. Marsteller0Diana J. Fregoso1Tricia L. Morphew2Inderpal S. Randhawa3The Translational Pulmonary and Immunology Research Center (TPIRC), Long Beach, CA 90806, USAThe Translational Pulmonary and Immunology Research Center (TPIRC), Long Beach, CA 90806, USAMorphew Consulting, LLC, Bothell, WA 98021, USAThe Translational Pulmonary and Immunology Research Center (TPIRC), Long Beach, CA 90806, USADisease-specific COVID-19 pediatric comorbidity has not been studied effectively to date. Atopy and food anaphylaxis disease states require improved characterization of SARS-CoV-2 infection risk. To provide the first such characterization, we assessed serum samples of a highly atopic, food anaphylactic, asymptomatic pediatric cohort from across the US during the height of the pandemic. From our biobank, 172 pediatric patient serum samples were characterized specific to atopic, food anaphylactic, and immunologic markers in the US at the beginning of the pandemic, from 1 February to 20 April 2020. Clinical and demographic data were further analyzed in addition to sample analysis for SARS-CoV-2 IgM and IgG ELISA. SARS-CoV-2 antibody results were positive in six patients (4%). Nearly half of the pediatric patients had a history of asthma (49%). Total IgE, total IgG, and IgG1-3 were similar in those positive and negative to SARS-CoV-2. Median total IgG4 in the SARS-CoV-2 positive group was nearly three times (<i>p</i>-value = 0.02) that of the negative group. Atopy controller medications did not confer additional benefit. Our data suggest that food anaphylaxis and highly atopic children are not at increased risk for SARS-CoV-2 seropositivity. This specific population appears either at equal or potentially less risk than the general population. Total and specific IgG4 may be a novel predictor of SARS-CoV-2 infection risk specific to the allergic pediatric population.https://www.mdpi.com/2073-4468/10/2/22antibodyatopyinfectious disease |
spellingShingle | Nathan L. Marsteller Diana J. Fregoso Tricia L. Morphew Inderpal S. Randhawa Immune Response to SARS-CoV-2 in an Asymptomatic Pediatric Allergic Cohort Antibodies antibody atopy infectious disease |
title | Immune Response to SARS-CoV-2 in an Asymptomatic Pediatric Allergic Cohort |
title_full | Immune Response to SARS-CoV-2 in an Asymptomatic Pediatric Allergic Cohort |
title_fullStr | Immune Response to SARS-CoV-2 in an Asymptomatic Pediatric Allergic Cohort |
title_full_unstemmed | Immune Response to SARS-CoV-2 in an Asymptomatic Pediatric Allergic Cohort |
title_short | Immune Response to SARS-CoV-2 in an Asymptomatic Pediatric Allergic Cohort |
title_sort | immune response to sars cov 2 in an asymptomatic pediatric allergic cohort |
topic | antibody atopy infectious disease |
url | https://www.mdpi.com/2073-4468/10/2/22 |
work_keys_str_mv | AT nathanlmarsteller immuneresponsetosarscov2inanasymptomaticpediatricallergiccohort AT dianajfregoso immuneresponsetosarscov2inanasymptomaticpediatricallergiccohort AT tricialmorphew immuneresponsetosarscov2inanasymptomaticpediatricallergiccohort AT inderpalsrandhawa immuneresponsetosarscov2inanasymptomaticpediatricallergiccohort |